DEPRESSION & ANXIETY

Carmina R. Fumaz Clinical Psychologist, Ph.D. Infectious Disease Service Germans Trias I Pujol University Hospital









Speaker and Research Grants:

- ViiV Healthcare
- Merck, Sharp & Dohme
- Gilead Sciences





- 1. Depression and Anxiety in our world...in PLWHIV (aging)
- 2. Main factors associated
- 3. How we can contribute to be, to alleviate, to help




Depression & Anxiety in our world

Mental illnesses prevalence, World, 2019



The estimated share of people with each mental illness in a given year, whether or not they were diagnosed, based on representative surveys, medical data and statistical modeling.





	Major depressive disorder, per 100 000 population				Anxiety disorders, per 100 000 population					
	Baseline (95% UI)	Additional (95% UI)	Final (95% UI)	Percentage change (95% UI)	Baseline (95% UI)	Additional (95% UI)	Final (95% UI)	Percentage change (95% UI)		
Global	2470·5	682·4	3152·9	27·6	3824·9	977·5	4802·4	25·6		
	(2143·5-2870·7)	(574·1-807·2)	(2722·5–3654·5)	(25·1–30·3)	(3283·3-4468·1)	(824·8–1161·6)	(4108·2–5588·6)	(23·2–28·0)		
Central Europe, eastern	2519-7	741·6	3261-3	29·4	3274·3	981-0	4255·3	30·0		
Europe, and central Asia	(2185-0-2911-5)	(579·1–941·3)	(2798-6-3804-8)	(23·9-35·8)	(2801·2-3821·9)	(774-1-1214-4)	(3593·1-4970·8)	(24·9–35·0)		
High-income	3103·3	840·1	3943·3	27·1	5356-8	1349·0	6705·7	25·2		
	(2735·6-3526·4)	(671·7-1030·4)	(3466·9-4516·1)	(22·6–31·5)	(4609-1-6233-3)	(1044·1-1678·8)	(5773·4-7829·4)	(20·3–30·7)		
Latin America and	2626-8	914-2	3541·0	34·8	5705-9	1804·1	7510·0	31·7		
Caribbean	(2291-4-3034-4)	(737-4-1127-5)	(3063·3-4097·7)	(29·5-40·7)	(4865-4-6732-9)	(1425·8–2225·1)	(6397·9–8786·6)	(25·8–37·7)		
North Africa and Middle	3321·4	1235-2	4556-6	37·2	5148·9	1664·8	6813·6	32·4		
East	(2752·3-4013·2)	(896-1-1642-5)	(3729-1-5578-3)	(29·5-46·0)	(4210·4-6289·4)	(1178·0-2251·6)	(5557·9-8391·8)	(24·9-41·1)		
South Asia	2664-2	962·6	3626-8	36·1	3019·7	1058-3	4077·9	35·1		
	(2313-9-3099-5)	(761·6–1187·1)	(3122-5-4232-7)	(29·7-42·8)	(2590·4-3531·6)	(813-0-1318-7)	(3459·3-4786·7)	(28·2-42·0)		
Southeast Asia, east Asia, and Oceania	1707·8	195·8	1903-6	11·5	3367-2	466·0	3833·2	13·8		
	(1492·4-1958·7)	(121·8–281·4)	(1656-1-2194-3)	(7·2-16·0)	(2903-3-3891-5)	(307·2-632·0)	(3281·8-4478·2)	(9·3-18·3)		
Sub-Saharan A frica	2429·0	559·0	2988-0	23·0	3001·9	644-0	3645·9	21·5		
	(2048·0–2910·2)	(423·3–722·8)	(2513-5-3583-4)	(18·3–27·9)	(2465·1-3671·3)	(479-0-829-9)	(2985·7-4475·5)	(17·1–25·7)		

UI-uncertainty interval.

Table 3: Prevalence of major depressive disorder and anxiety disorders, by super-region, 2020

Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

Lancet 2021; 398: 1700-12






Figure 1: Global prevalence of major depressive disorder (A) and anxiety disorders (B) before and after adjustment for (ie, during) the COVID-19 pandemic, 2020, by age and sex






Figure 3: Change in the prevalence of anxiety disorders after adjustment for (ie, during) the COVID-19 pandemic, 2020

Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic


Lancet 2021; 398: 1700-12

People tend to forget past episodes of depression





The same group of people were interviewed several times, years apart, about lifetime depression. This shows the share who recalled having an episode of depression.



Yoichiro Takayanagi et al. (2014). Accuracy of reports of lifetime mental and physical disorders. JAMA Psychiatry.



Depression & Anxiety in PLWHIV (aging)



☐ A multi-site cohort study of over 1.500 PLWHIV found lifetime depressive symptom rates of 63%.
□ Across multiple studies diagnosis of lifetime Major Depressive Disorders ranges from 22-54% in PLWHIV, compared to 4.9-17.1% lifetime Major Depressive Disorders diagnosis in the general U.S. population.
☐ These medical and psychological factors may be exacerbated in older PLWHIV who are often burdened to a higher degree with HIV-related medical and psychological factors, in conjunction with aging related problems.




☐ The study period was from Jan 1st 2000, to Jan 1st 2020. ☐ Of 7167 people living with HIV without mental illness at baseline, 586 developed a mental illness (incidence rate 19.6 per 1000 person-years) compared with 418 of 7167 people without HIV (incidence rate 12.1 per 1000 person-years), resulting in an adjusted hazard ratio (HR) of 1.63 (95%) CI 1.44-1.85). ☐ People living with HIV had higher incidence rates for depression (15.4 per 1000 person-years), anxiety (7.2 per 1000 person-years), and severe mental illness (1.6 per 1000 person-years) compared with people without HIV (7.9, 5.0, and 0.6 per 1000 person-years, respectively). with

adjusted HRs of 1.94 (95% CI 1.68-2.24) for depression, 1.38 (1.15-1.66) for

Gooden et al. The risk of mental illness in people living with HIV in the UK: a propensity score-matched cohort study. The Lancet HIV 2022.

anxiety, and 2.18 (1.41-3.39) for severe mental illness.






Rooney AS et al. Depression and aging with HIV: Associations with health-related quality of life and positive psychological factors. Affect Disord 2019.



Main factors associated


Conceptual model used in the CHANGE HIV study design





Age 65 and older







STIGMA SOCIAL SUPPORT PAIN

Opinion of the Speaker



STIGMA

AGEISM

+

HIV INFECTION

Current Epidemiology Reports (2021) 8:72–78 https://doi.org/10.1007/s40471-021-00265-6

EPIDEMIOLOGY OF AGING (K LAPANE, SECTION EDITOR)



HIV and Aging: Double Stigma

Monique J. Brown 1,2,3,4 🕞 • Oluwafemi Adeagbo 2,5,6





Loneliness, HRQOL and functional impairment



	N with poor/fair	Unadjusted PR (95%	Adjusted ^a PR (95%
	health	CI)	CI)
Loneliness ^b (per 5 point increase)		1.36 (1.13-1.63)	1.06 (0.85-1.33)
Age ^c		0.98 (0.94 1.01)	
Male sex at birth ^c	91	0.95 (0.55-1.63)	
Non-white race ^c	52	1.34 (0.92-1.97)	
Latino ethnicity	17	1.67 (0.99-2.81)	
Annual income			
< \$10,000	41	2.58 (1.50-4.45)	1.85 (1.05-3.28)
\$10,000-20,000	39	1.98 (1.15-3.43)	1.60 (0.90-2.84)
≥ \$20,001 (reference)	19	1.0	1.0
VACS index ^d		1.07 (0.96-1.19)	1.03 (0.92-1.16)
Length of time with HIV (years) ^e		1.07 (0.94-1.23)	
Depressive symptoms by PHQ-9 ^f			
None (reference)	19	1.0	1.0
Mild	30	2.57 (1.45-4.56)	2.19 (1.17-1.12)
Mod	31	5.15 (2.91-9.12)	4.18 (2.14-8.16)
Severe	24	4.84 (2.65-8.84)	4.34 (2.13-8.85)
Education			
< High school	15	2.06 (0.97-4.41)	
High school	21	2.14 (1.05-4.35)	
Some college/college degree	58	1.87 (1.0-3.47)	
Some graduate/graduate degree	12	1.0	


Association of loneliness symptoms and functional impairment (dependent with ≥ 1 Instrumental Activities of Daily Living) Confidence intervals that do not include 1.0 are shown in bold

	N dependent with ≥ 1 IADL	Unadjusted PR (95% CI)	Adjusted ^a PR (95% CI)		
Loneliness ^b (per 5 point increase)		1.19 (1.01-1.40)	1.02 (0.84-1.24)		
Age ^c		0.90 (0.96-1.02)			
Male sex at birth ^c	106	0.56 (0.37-0.84)			
Non-white race ^c	71	1.48 (1.06-2.08)			
Latino ethnicity	19	1.33 (0.82-2.16)			
Annual income					
< \$10,000	52	2.68 (1.64-4.38)	2.03 (1.21-3.42)		
\$10,000-20,000	53	2.30 (1.41-3.76)	1.90 (1.14-3.17)		
≥ \$20,001 (reference)	23	1.0	1.0		
VACS index ^d (per 10 point increase)		1.15 (1.05-1.26)	1.14 (1.03-1.25)		
Length of time with HIV infection (years) ^e		1.11 (0.98-1.25)			
Depressive symptoms by PHQ-9 ^f					
None (reference)	34	1.0	1.0		
Mild	49	2.31 (1.49-3.58)	2.08 (1.27-3.41)		
Mod	29	2.58 (1.57-4.22)	2.26 (1.26-4.06)		
Severe	22	2.48 (1.45-4.24)	2.36 (1.23-4.52)		
Education					
< High school	22	1.94 (1.04-3.63)			
High school	33	2.25 (1.27-4.00)			
Some college/college degree	63	1.37 (0.81-2.31)			

Greene M et al. Loneliness in Older Adults Living with HIV. AIDS Behav 2018.

Loneliness and inflammation





Higher loneliness scores (UCLA-3 Total scores), in conjunction with high D-dimer values, contributed to an additive effect on depressive symptoms (CES-D Total scores) in PWH





Pain



Indirect effect of pain (ab) = -.003, 95% CI = -.006 to -.0005




FIGURE 1. Exploratory mediation model suggesting that depressive symptoms are related to slower gait speed in part via worse pain. The figure notes the estimated effect for each path, with standard errors in parentheses. The * symbol indicates a statistically significant effect at an α level of .050. The model adjusted for age, sex, race, disease burden, body mass index, smoking status, selective scrotonin reuptake inhibitor medications, analgesic opioid medications, and time since HIV diagnosis. CI = confidence interval.

Age 54 to 78

Derry-Vick HM et al. Pain Is Associated With Depressive Symptoms, Inflammation, and Poorer Physical Function in Older Adults With HIV. Psychosom Med 2022



How we can contribute to be, to alleviate, to help

1. Boost your empathy



- ☐ Ways to **strengthen**
- Walk in others' shoes
- Examine your biases
- Detect your prejudices (about aging, about being ill...)
- Cultivate your sense of curiosity

2. Create a safe space



- ☐ Train yourself to **communicate better**
- Be respectful
- Be assertive, do not fear to ask
- Use non verbal language, gestures
- Work the therapeutic bond
- Include always the patient in each decision
- Stop looking at the computer...

Patient Health Questionnaire-2 (PHQ-2)

⋈ Share

The PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks. The PHQ-2 includes the first two items of the PHQ-9.

- The purpose of the PHQ-2 is to screen for depression in a "first-step" approach.
- Patients who screen positive should be further evaluated with the PHQ-9 to determine whether they meet criteria for a depressive disorder.

Over the <u>last 2 weeks</u> , how often have you been bothered by the following problems?	Not at all	Several days	More than half the days	Nearly every day
Little interest or pleasure in doing things	0 0	O +1	O +2	O +3
Feeling down, depressed or hopeless	0 0	O +1	O +2	O +3

PHQ-2 score obtained by adding score for each question (total points)

Interpretation:

- A PHQ-2 score ranges from 0-6. The authors identified a score of 3 as the optimal cutpoint when using the PHQ-2 to screen for depression.
- If the score is 3 or greater, major depressive disorder is likely.
- Patients who screen positive should be further evaluated with the PHQ-9, other diagnostic instruments, or direct interview to determine whether they meet criteria for a depressive disorder.

3. Explore easily



Generalized Anxiety Disorder 2-item (GAD-2) The Generalized Anxiety Disorder 2-item (GAD-2) is a very brief and easy to perform initial screening tool for generalized anxiety disorder.¹										
Over the <u>last 2 weeks</u> , how often have you been bothered by the following problems?	Not at all		Several days		More than half the days		Nearly every day			
Feeling nervous, anxious or on edge	0 0		0	+1		0	+2		0	+3
Not being able to stop or control worrying	0 0		0	+1		0	+2		0	+3

GAD-2 score obtained by adding score for each question (total points)

Interpretation:

A score of 3 points is the preferred cut-off for identifying possible cases and in which further diagnostic evaluation for generalized anxiety disorder is warranted. Using a cut-off of 3 the GAD-2 has a sensitivity of 86% and specificity of 83% for diagnosis generalized anxiety disorder.

4. Identify available resources



- Emergency help
- Local services
- Community resources



Free Image Dan Meyers



Than (5

Any questions?

You can find me at cfumaz@lluita.org